Brief: Adicet Bio Reports Positive Data From AdI-001 Phase 1 Trial In Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
26/06/2023 21:18
June 26 (Reuters) - Adicet Bio Inc ACET.O :
* ADICET BIO REPORTS POSITIVE DATA FROM ONGOING ADI-001
PHASE 1
TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL
NON-HODGKIN’S LYMPHOMA (NHL)
* ADICET BIO INC - CLINICAL UPDATE FROM ADDITIONAL POST-CAR
T LBCL
PATIENTS EXPECTED IN SECOND HALF OF 2024
* ADICET BIO- PLAN TO TRANSITION ADI-001 PROGRAM INTO
POTENTIALLY
PIVOTAL PHASE 2 STUDY IN POST-CAR T LARGE B-CELL LYMPHOMA
PATIENTS IN H1 OF 2024
* ADICET BIO- TRIAL SHOWED FAVORABLE SAFETY WITH NO
SIGNIFICANT
INCIDENCE OF CRS OR ICANS
Source text for Eikon: ID:nBw5B7t2qa
Further company coverage: ACET.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary